Table 1.
Patient and disease characteristics
| Patient and disease characteristics | Part 1 GSK3174998 (n=45) |
Part 2 GSK3174998+pembrolizumab (n=96) |
| Age, years; median (range) | 63.0 (27–78) | 63.5 (25–86) |
| Sex, n (%) | ||
| Female | 27 (60) | 44 (46) |
| Male | 18 (40) | 52 (54) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 6 (13) | 3 (3) |
| Not Hispanic or Latino | 39 (87) | 91 (95) |
| Race, n (%) | ||
| African American/African Heritage | 2 (4) | 4 (4) |
| Asian—Central/South Asian Heritage | 1 (2) | 0 |
| Asian—East Asian Heritage | 0 | 3 (3) |
| Asian—Southeast Asian Heritage | 1 (2) | 2 (2) |
| White—Arabic/North African Heritage | 2 (4) | 1 (1) |
| White—white/Caucasian/European Heritage | 38 (84) | 82 (85) |
| ECOG PS, n (%) | ||
| 0 | 20 (44) | 38 (40) |
| 1 | 25 (56) | 58 (60) |
| Tumor types, n (%) | ||
| NSCLC | 12 (27) | 17 (18) |
| Melanoma | 3 (7) | 20 (21) |
| STS | 10 (22) | 8 (8) |
| CRC MSI-H | 1 (2) | 13 (14) |
| RCC | 8 (18) | 9 (9) |
| Bladder | 2 (4) | 11 (11) |
| HNSCC | 2 (4) | 7 (7) |
| TNBC | 7 (16) | 11 (11) |
| Median time since initial diagnosis, months (range) | 21.0 (1–227) | 25.0 (2–173) |
| Prior anticancer therapy regimens, n (%) | ||
| 1–2 | 19 (42) | 45 (47) |
| ≥3 | 24 (53) | 46 (48) |
| Prior PD-(L)1 therapy, n (%) | 13 (29) | 41 (43) |
| Nivolumab | 7 (16) | 30 (31) |
| Pembrolizumab | 5 (11) | 15 (16) |
| Other PD-(L)1 blocker | 3 (7) | 7 (7) |
CRC MSI-H, colorectal carcinoma displaying high microsatellite instability; ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death 1 protein; PD-L1, programmed cell death 1 ligand; RCC, renal cell carcinoma; STS, soft tissue sarcoma; TNBC, triple-negative breast cancer.